AlphAIAlphAI — Financial news for AI agents
finanznachrichten.de$ANIX

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

Original reporting
finanznachrichten.de
Published Sep 11, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ANIX
Bullish
high confidence
Mentioned
$ANIX · $NXL
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ANIXBullishMed
01

Why it matters

Both companies disclose material clinical progress, providing fresh data that could influence investor sentiment and short‑term price movements.

02

Market read

Early trial success and upcoming pivotal study are primary catalysts for these micro‑caps, potentially driving short‑term trading interest.

03

What to watch

Funding sources and partnership terms with Cleveland Clinic and defense contracts could affect long‑term valuation.

Relevance 8/10Novelty 8/10Timing: upcoming broadcast Sep 12‑13

Background

The article announces televised interviews for Anixa Biosciences (ANIX) and Nexalin Technology (NXL) highlighting recent trial results and upcoming FDA plans.

Company-level read

Ticker impact

$ANIXBullishHigh confidence
Context

Announced Phase 1 breast cancer vaccine trial met endpoints, 74% immune response, no safety issues.

Expected impact

potential upside of 10-15% if data is confirmed by market.

Evidence & confidence

Phase 1 success is material for a clinical-stage biotech; investors react to early efficacy signals.

$NXLNeutralMedium confidence
Context

Provided details on upcoming pivotal insomnia trial and FDA de novo submission plan.

Expected impact

modest upside of 5-8% if trial design is viewed favorably.

Evidence & confidence

Trial is a near‑term catalyst but outcome is uncertain; market may price in potential.

Market effects

Sector

Positive early data may lift broader biotech and neurostimulation sectors.

Regional

US micro‑cap biotech and med‑tech markets could see modest inflows.

Global

Limited to investors focused on clinical‑stage biotech and device companies.

Counterpoint

What could challenge this read

Phase 1 data may be overhyped; without Phase 2 results, price could be volatile.

Key entities

  • company
    Anixa Biosciences, Inc.

    Clinical‑stage biotech developing breast cancer vaccine.

  • company
    Nexalin Technology, Inc.

    Developer of non‑invasive neurostimulation devices.

Read at source← All news

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

investing.com
$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

prnewswire.com
$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

stocktitan.net
$NXLHighAI 8/10

Nexalin study shows sleep improvement in Alzheimer’s patients

Nexalin Technology (NASDAQ:NXL) published study results showing its brain stimulation device improved sleep quality in mild Alzheimer’s patients. The trial, funded by China's National Key R&D Program, found significant sleep quality improvements in the active treatment group. The device is approved in China, Brazil, and Israel but remains investigational in the U.S.

investing.com
$ANIXLowAI 8/10

Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

investing.com